Cited by 100Chronic Obstructive Pulmonary Disease (COPD) ResearchMetabolism, Diabetes, and CancerCystic Fibrosis Research Advances

Metformin: Experimental and Clinical Evidence for a Potential Role in Emphysema Treatment

Open access
Polverino, Francesca, Wu, Tianshi David, Rojas-Quintero, Joselyn, Wang, Xiaoyun, Mayo, Jonathan, Tomchaney, Michael, Tram, Judy, Packard, Samuel +20 more·2021·American Journal of Respiratory and Critical Care Medicine

Abstract

Rationale: Cigarette smoke (CS) inhalation triggers oxidative stress and inflammation, leading to accelerated lung aging, apoptosis, and emphysema, as well as systemic pathologies. Metformin is beneficial for protecting against aging-related diseases. Objectives: We sought to investigate whether metformin may ameliorate CS-induced pathologies of emphysematous chronic obstructive pulmonary disease (COPD). Methods: Mice were exposed chronically to CS and fed metformin-enriched chow for the second half of exposure. Lung, kidney, and muscle pathologies, lung proteostasis, endoplasmic reticulum (ER) stress, mitochondrial function, and mediators of metformin effects in vivo and/or in vitrowere studied. We evaluated the association of metformin use with indices of emphysema progression over 5 years of follow-up among the COPDGene (Genetic Epidemiology of COPD) study participants. The association of metformin use with the percentage of emphysema and adjusted lung density was estimated by using a linear mixed model. Measurements and Main Results: Metformin protected against CS-induced pulmonary inflammation and airspace enlargement; small airway remodeling, glomerular shrinkage, oxidative stress, apoptosis, telomere damage, aging, dysmetabolism in vivo and in vitro; and ER stress. The AMPK (AMP-activated protein kinase) pathway was central to metformin’s protective action. Within COPDGene, participants receiving metformin compared with those not receiving it had a slower progression of emphysema (−0.92%; 95% confidence interval [CI], −1.7% to −0.14%; P = 0.02) and a slower adjusted lung density decrease (2.2 g/L; 95% CI, 0.43 to 4.0 g/L; P = 0.01). Conclusions: Metformin protected against CS-induced lung, renal, and muscle injury; mitochondrial dysfunction; and unfolded protein responses and ER stress in mice. In humans, metformin use was associated with lesser emphysema progression over time. Our results provide a rationale for clinical trials testing the efficacy of metformin in limiting emphysema progression and its systemic consequences.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.202012-4510oc

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Metformin has been shown to protect against CS-induced myofiber type switch and telomere shortening in a mouse model of emphysema, mediated by activation of AMPK and GDF-15.

    “On a therapeutic prospect, the metabolic modulator metformin has been shown to be able to protect against CS-induced myofibers’ type switch and telomere shortening in a mouse model of emphysema, mediated by the activation of 5′AMPK (AMP-activated protein kinase) and GDF-15 (growth differentiation factor 15) [146].”

    From Main Pathogenic Mechanisms and Recent Advances in COPD Peripheral Skeletal Muscle Wasting (2023) · cites this paper as [146]

    The Results report that metformin-treated, cigarette-smoke-exposed mice had longer quadriceps telomeres and were partially protected against loss of type I muscle fibers. The Abstract and Discussion link metformin’s protective effects to AMPK and GDF-15 activation, but do not establish that activation of both mediates these specific muscle and telomere effects. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Polverino, F., Wu, T. D., Rojas-Quintero, J., Wang, X., Mayo, J., Tomchaney, M., Tram, J., Packard, S., Zhang, D., Cleveland, K. H., Cordoba-Lanus, E., Owen, C. A., Fawzy, A., Kinney, G. L., Hersh, C. P., Hansel, N. N., Doubleday, K., Sauler, M., Tesfaigzi, Y., Ledford, J. G., Casanova, C., Zmijewski, J., Konhilas, J., Langlais, P. R., Schnellmann, R., Rahman, I., McCormack, M., & Celli, B.
Affiliations
  • Asthma and Airway Disease Research Center and
  • Michael E. DeBakey VA Medical Center (US)
  • Division of Pulmonary and Critical Care Medicine and
  • University of Georgia (US)
  • College of Pharmacy, and
  • Servicio de Neumología, Unidad de Investigación, Hospital Universitario La Candelaria, Santa Cruz de Tenerife, Tenerife, Spain
  • Johns Hopkins University (US)
  • Department of Epidemiology, Colorado School of Public Health, Aurora, Colorado
  • Brigham and Women's Hospital (US)
  • Division of Endocrinology, Department of Medicine
  • Yale University (US)
  • Hospital Universitario Nuestra Señora de Candelaria (ES)
  • University of Alabama at Birmingham (US)
  • University of Arizona (US)
  • University of Rochester Medicine (US)
Corresponding author
Polverino, Francesca
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2021-09
Volume
204
Issue
6
Pages
651-666
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W3164074497
Cited by
100
References
52
Citations by year
2026: 15 · 2025: 17 · 2024: 19 · 2023: 28 · 2022: 16 · 2021: 5
FWCI
11.04
Type
journal article
Language
en
Open access
Locations
  • American Journal of Respiratory and Critical Care Medicine (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (UL1TR001863)
  • National Heart, Lung, and Blood Institute (K08HL135402, U01HL089856, U01HL089897, R01HL149744, R01HL155948, R01HL142769, R01HL132523, R01HL139617)
  • National Institute of Environmental Health Sciences (P50ES018176, T32ES007091)
  • National Center for Advancing Translational Sciences
  • National Institute on Minority Health and Health Disparities (P50MD010431)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
Keywords
metformin, emphysema, chronic obstructive pulmonary disease, cigarette smoke, AMPK signaling, endoplasmic reticulum stress, oxidative stress, mitochondrial dysfunction, aging, COPDGene, lung aging, kidney injury, muscle damage, small airway remodeling, emphysema progression
MeSH terms
Cigarette Smoking, Aged, Aged, 80 and over, Animals, Female, Follow-Up Studies, Humans, Male, Metformin, Mice, Inbred C57BL, Middle Aged, Pulmonary Emphysema, Biomarkers, Treatment Outcome, Disease Progression, Protective Agents, Pulmonary Disease, Chronic Obstructive, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review